Mangoceuticals, Inc.
MGRX
$0.36
$0.025.60%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -28.07% | 12.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -28.07% | 12.11% | |||
| Cost of Revenue | -17.06% | 40.84% | |||
| Gross Profit | -38.95% | -6.68% | |||
| SG&A Expenses | 662.28% | -94.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 101.13% | -79.17% | |||
| Operating Income | -109.34% | 80.19% | |||
| Income Before Tax | -22.88% | 63.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.88% | 63.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 100.00% | -133.33% | |||
| Net Income | -22.88% | 63.64% | |||
| EBIT | -109.34% | 80.19% | |||
| EBITDA | -171.56% | 86.11% | |||
| EPS Basic | -3.89% | 68.56% | |||
| Normalized Basic EPS | -94.14% | 83.90% | |||
| EPS Diluted | -3.89% | 68.56% | |||
| Normalized Diluted EPS | -94.14% | 83.90% | |||
| Average Basic Shares Outstanding | 16.16% | 23.12% | |||
| Average Diluted Shares Outstanding | 16.16% | 23.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||